Guggenheim reiterated their neutral rating on shares of Biogen (NASDAQ:BIIB) in a research note issued to investors on Thursday morning, MarketBeat.com reports. They currently have a $325.00 target price on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on BIIB. Oppenheimer set a $372.00 price target on shares of Biogen and gave the company a buy rating in a research note on Friday, January 25th. Stifel Nicolaus cut shares of Biogen from a buy rating to a hold rating and dropped their price target for the company from $397.00 to $346.00 in a research note on Thursday, February 21st. Mizuho set a $427.00 price target on shares of Biogen and gave the company a buy rating in a research note on Tuesday, January 29th. Leerink Swann lifted their price target on shares of Biogen from $328.00 to $341.00 and gave the company a market perform rating in a research note on Wednesday, January 30th. Finally, Citigroup lifted their price target on shares of Biogen from $372.00 to $380.00 and gave the company an outperform rating in a research note on Wednesday, January 30th. Two equities research analysts have rated the stock with a sell rating, twenty-one have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $306.39.

NASDAQ:BIIB opened at $216.71 on Thursday. The company has a quick ratio of 2.04, a current ratio of 2.32 and a debt-to-equity ratio of 0.46. The company has a market cap of $42.63 billion, a PE ratio of 8.27, a PEG ratio of 0.82 and a beta of 1.09. Biogen has a 1-year low of $216.49 and a 1-year high of $388.67.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, January 29th. The biotechnology company reported $6.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.72 by $0.27. Biogen had a net margin of 32.94% and a return on equity of 40.53%. The firm had revenue of $3.53 billion for the quarter, compared to analysts’ expectations of $3.39 billion. During the same quarter last year, the company earned $5.26 EPS. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. Analysts expect that Biogen will post 28.68 earnings per share for the current fiscal year.

In other Biogen news, Director Alexander J. Denner bought 7,000 shares of the stock in a transaction on Friday, February 1st. The shares were bought at an average price of $328.45 per share, with a total value of $2,299,150.00. Following the purchase, the director now directly owns 10,909 shares in the company, valued at approximately $3,583,061.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alexander J. Denner bought 30,000 shares of the stock in a transaction on Wednesday, January 30th. The shares were acquired at an average cost of $324.86 per share, for a total transaction of $9,745,800.00. Following the purchase, the director now owns 10,909 shares in the company, valued at $3,543,897.74. The disclosure for this purchase can be found here. Insiders own 0.29% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in BIIB. Portfolio Solutions LLC acquired a new position in shares of Biogen during the 4th quarter valued at about $26,000. Doyle Wealth Management acquired a new position in shares of Biogen during the 4th quarter valued at about $32,000. IMS Capital Management acquired a new position in shares of Biogen during the 3rd quarter valued at about $38,000. Jackson Grant Investment Advisers Inc. acquired a new position in shares of Biogen during the 4th quarter valued at about $40,000. Finally, Moody National Bank Trust Division acquired a new position in shares of Biogen during the 4th quarter valued at about $41,000. 87.96% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Featured Story: Quiet Period

Analyst Recommendations for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.